arry-382
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2011 (NCT01316822)
Timeline
2010s
- Jan 1, 2011
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
CSF1R inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cc1cccc(Cn2nc(C3CC3)c3c(NC(=O)c4cnc5cc(OCCN6CCN(C)CC6)ccn45)cccc32)n1- Mol. weight
- 564.69 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3644252 ↗
- ChEMBLCHEMBL3544959 ↗
Also known as
- arry-382
- arry-382
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02880371 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2016 | Array BioPharma |
| NCT01316822 | Phase 1 | Mar 1, 2011 | Array BioPharma |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Array BioPharma | For profit | 2 | 2 | 2 | 2011 |
1 organizations
Page 1 / 1